Posted by Michael Wonder on 13 May 2017
Institute for Clinical and Economic Review releases revised evidence report on dupilumab and crisaborole for treatment of atopic dermatitis
12 May 2017 - Limitations noted on the evidence for crisaborole; analyses find stronger evidence for dupilumab and suggest its price has been set to align fairly with its added benefit for patients.
The Institute for Clinical and Economic Review (ICER) has released an Evidence Report assessing the comparative clinical effectiveness and value of dupilumab and crisaborole for the treatment of atopic dermatitis. This evidence report will be the subject of the upcoming public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) on 25 May 2017.
The report evaluates the evidence on dupilumab (Dupixent, Sanofi-Regeneron), an injectable treatment for moderate-to-severe atopic dermatitis, and crisaborole (Eucrisa, Pfizer), a topical treatment for mild-to-moderate atopic dermatitis, focusing on the clinical benefits, side effects, and value of these therapies compared to other treatment options available.
